Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Absolute Bioavailability and ADME of TAK-935 in Healthy Adult Male Participants
NCT04992442Phase 1Completed
- Sponsor
- Takeda
- Start
- Jul 2020
- Primary completion
- Aug 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of soticlestat in epilepsy, sponsored by Takeda. Primary endpoints: Percent Absolute Bioavailability (%F) for TAK-935 up to 48 hours, Total Radioactivity Expressed as Cumulative Percentage of Dose of [14C]TAK-935 Excreted in Urine and Feces Combined up to 120 hours and 26 more. Started Jul 2020; status: completed.
02
Drugs
soticlestat
03
Conditions
epilepsy
Beyond the preview
Go deeper on NCT04992442.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04992442.